« Back to news

Ventus Therapeutics Promotes Daniel Koerwer to Chief Operating Officer

WALTHAM, Mass. & MONTREAL, QC — July 7, 2022 —Ventus Therapeutics, Inc., a biopharmaceutical company leading a renaissance in the discovery and development of small molecule medicines by utilizing structural biology and a proprietary computational platform, today announced the promotion of Daniel Koerwer from Chief Business Officer to Chief Operating Officer. In this new role, in addition to corporate and business development, Mr. Koerwer will be responsible for several key areas, including intellectual property, human resources, company operations, and competitive intelligence.

“Since joining Ventus, Dan has been instrumental in the overall growth and strategy of our company,” said Marcelo Bigal, M.D., Ph.D., President and CEO at Ventus. “Dan’s promotion reflects the significant impact he has had across the breadth of Ventus’ operations to date. Dan is an established leader and I look forward to working with him in an expanded role to bring the operational excellence necessary to advance our disruptive ReSOLVE platform and our pipeline of innovative novel small molecule medicines.”

Mr. Koerwer has more than 20 years of experience in the biotech industry, with expertise in business development, corporate development, and commercial operations in the U.S. and abroad. Prior to joining Ventus, Mr. Koerwer was the Chief Business Officer at Arrakis Therapeutics and BIND Therapeutics. Previously, he served as President of Biogen’s biosimilars business and held leadership positions in the company’s corporate development, discovery research, and commercial operations groups. Mr. Koerwer received his M.B.A. from Harvard University and B.S. in biochemistry from Boston College.

“Ventus has grown exponentially in the last three years, culminating in the completion of multiple financing rounds with top-tier investors and the continued advancement of a promising pipeline and differentiated platform,” said Mr. Koerwer. “There is still plenty to do in bringing these small molecule therapies to patients, and we are well positioned to continue our upward trajectory.”

About Ventus Therapeutics
Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company’s proprietary drug discovery platform, ReSOLVE, gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated small molecule medicines. The Company’s lead programs target key innate immune modulators, including NLRP3 and cGAS. The Company aims to address the needs of patients by using its ReSOLVE platform to improve the way medicines are discovered and developed, with the ultimate goal of positively impacting patient outcomes. For more information, please visit www.ventustx.com and engage with the Company on Twitter @Ventus_Tx or on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of the executive leadership team, our business strategy, current programs, future results of operations, and financial position. These forward-looking statements are based on our current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving our development programs; the results of our earlier studies not being predictive of future results; our ability to enhance the ReSOLVE platform; our ability to continue to obtain funding for our operations and implement our business strategy; the impact of the COVID-19 pandemic on our business and our efforts to address its impact on our business; anticipated developments related to our competitors and our industry; the performance of third-party service providers, including suppliers and manufacturers; and our ability to obtain, maintain, and protect our intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and we undertake no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

Media Contact:
Alexis Feinberg
ICR Westwicke